No Data
Shanghai Pharmaceuticals' 2024 Profit Jumps 21%, Revenue Up 6%
The optimization policy direction for drug central purchasing is a hot topic: overcoming the "Low Stock Price" phenomenon and guiding quality supervision.
① The government work report on March 5 mentioned the need to "optimize the Pharmaceutical and consumables centralized procurement policy"; ② From the overall trend of optimizing the centralized procurement policy, there is a greater emphasis on moderate price reductions and quality supervision, and the concentration of the Industry is expected to further increase.
BD Trade resolves financing difficulties! Industry: Innovative Drugs have survived, but the challenge of thriving is even greater.
① In 2024, license-out Trade has become an important way for Biotech to recover funds and increase revenue; ② The quality and standing of Innovative Drugs in China are gaining more international recognition; ③ Whether Innovative Drugs are worth investing in is related to the secondary market in the short term, but in the medium to long term, it depends on the improvement of the primary market exit channels, the payment environment for Innovative Drugs, and other issues.
Shanghai Pharmaceuticals: 2024 Annual Report of Shanghai Pharmaceutical Group Co., Ltd.
Shanghai Pharmaceuticals: Summary of the 2024 Annual Report of Shanghai Pharmaceutical Group Co., Ltd.
Summary of the 2024 Annual Report of Shanghai Pharmaceutical Group Co., Ltd.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
